Chirayu R. Chokshi

Chirayu R. Chokshi

Auto-generated profile, based on publicly available information

Chirayu R. Chokshi

McMaster University 1 Department of Biochemistry and Biomedical Sciences Hamilton, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CCChirayu R. Chokshi
Chirayu R. Chokshi
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
BBBenjamin Brakel
Benjamin Brakel
MRMartin A. Rossotti
Martin A. Rossotti
DTDavid Tieu
David Tieu
Sheila SinghSheila Singh
Sheila Singh

13 May 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
WMWilliam T. Maich
William T. Maich
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
APAnish Puri
Anish Puri
MRMartin A. Rossotti
Martin A. Rossotti
SGShan Grewal
Shan Grewal
Sheila SinghSheila Singh
Sheila Singh
Glioblastoma (GBM) comprises nearly 15% of primary central nervous system (CNS) tumors and 50% of malignant primary CNS tumors worldwide. Considerable tumoral heterogeneity exists in GBM, leading to inefficacy of current treatments and the absence of meaningful improvements in frontline therapies in the past 20 years. Through multiomic analysis of patient-derived primary and recurrent GBM cell lines, we identified the urokinase plasminogen activator receptor (uPAR) as a protumorigenic marker of putative brain tumor–initiating cells and a potential therapeutic target. We found that genetic disruption of uPAR expression impaired protumorigenic characteristics in vitro and in vivo, highlighting its biological role in tumorigenesis. We then generated uPAR-specific chimeric antigen receptor (CAR) T cells, which demonstrated potent antitumor activity in recurrent GBM patient–derived xenograft models. In addition to direct tumor cell killing, we found that uPAR is expressed on GBM-associated macrophages, enabling uPAR CAR T cells to target both GBM itself and cells in the tumor microenvironment. Together, these data illustrate the potency and therapeutic potential of targeting uPAR in GBM.

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Normalized gRNA read counts for chemoradiogenetic CRISPR-Cas9 screen in GBM model BT935, related to figure 2B

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
A) Immunoblotting of FEN1 protein in GSCs after knockout of FEN1 or AAVS1 (control), related to figure 2C and 2D. B) Immunoblotting of FEN1 protein in GSCs after knockdown of FEN1 or GFP (control), related to figure 2E.

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Sensitivity to FEN1 inhibition extends to TMZ sensitization. A, Cell viability assays of GSC and NSC lines exposed to increasing concentrations of FEN1 inhibitor over 7 days. Data are represented as mean ± SE; n = 4 experimental replicates. B, Cell viability assays of NSC, FEN1i-resistant, and FEN1i-sensitive GSC lines exposed to DMSO (control), 25 μmol/L TMZ, 30 μmol/L FEN1i, or combination (TMZ and FEN1i). Dashed lines represent expected viability under combination treatment. Data are represented as mean ± SE; n = 4 experimental replicates. C and D, Synergy assays between TMZ and FEN1 inhibitor in (C) FEN1i-resistant and (D) FEN1i-sensitive GBM models. Colors correspond to Bliss excess synergy scores, wherein more positive values indicate stronger synergy; n = 4 experimental replicates. ns, not statistically significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
CCChirayu R. Chokshi
Chirayu R. Chokshi
KBKevin Brown
Kevin Brown
CVChitra Venugopal
Chitra Venugopal
JMJason Moffat
Jason Moffat
Sheila SinghSheila Singh
Sheila Singh
Glioblastoma is a highly fatal brain cancer. The underlying functional drivers of treatment resistance and disease recurrence are unclear. By applying a genome-wide CRISPR-Cas9 library to patient-derived glioblastoma stem cell models, we systematically map genetic dependencies in patient-matched pre-treatment primary and post-treatment recurrent tumor cells. These insights reveal a large-scale remodelling of genetic dependency profiles at disease recurrence, arming recurrent tumor cells with newly-acquired genetic drivers and further loss of tumor suppressors. These analyses support parallel tumor-intrinsic mechanisms of treatment resistance which rely on acquisition of immunosuppressive capacity, including a defective mismatch repair pathway, ablation of PTEN activity, and a novel combination of de novo mutations in SWI/SNF components. We map a multilayered genetic and functional response to drive tumor recurrence, identifying protein tyrosine phosphatase 4A2 (PTP4A2) as a novel driver of self-renewal, proliferation and tumorigenicity at glioblastoma recurrence. Mechanistically, genetic perturbation and a small molecule inhibitor of PTP4A2 results in greater survival and reduced tumor growth in patient-derived models of recurrent glioblastoma. Citation Format: Chirayu R. Chokshi, Kevin Brown, Chitra Venugopal, Jason Moffat, Sheila K. Singh. Functional mapping reveals widespread remodelling and unrecognized pathway dependencies in recurrent glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 60.